Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Item

http://www.wikidata.org/entity/Q34679149

Q34679149

about

Cancer stem cell metabolism Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors Therapeutic targeting of cancers with loss of PTEN function.The Role of PTEN in Tumor Angiogenesis Dual HER2 blockade: preclinical and clinical data Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance PIK3R1 underexpression is an independent prognostic marker in breast cancer.Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma Targeting the HER/EGFR/ErbB family to prevent breast cancer.Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.Targeted therapies for breast cancer.Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer Will PI3K pathway inhibitors be effective as single agents in patients with cancer?Target points in trastuzumab resistance Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications

P2860

Q26746123-2205779C-7DD3-42E9-B348-1124FE109EBA Q26752780-1EAD0E68-71AC-4E45-98B3-E49CB283437D Q26785612-407F9B3D-0530-4B20-AF6D-2540DF060539 Q27001729-17B662F2-8A94-4752-8BDD-3506EA1ECD22 Q27679463-90FDE54C-C092-4422-92B1-8CDAD5B28345 Q27851705-A41AC78D-763D-4338-924F-AEB08FB89B3B Q27851975-E27A2F4C-3731-4989-9FA2-65B50E990D22 Q27852764-0D70DE2C-CDD0-4E3B-816D-ED73F0FCFFEE Q28391620-47284D49-86C6-43CB-B274-2BDAB4080D89 Q30941327-694B04E2-5B3C-4D1E-8DEA-01725E5B70E2 Q33571352-FD0CFFDC-2704-4611-99EF-F3FBC557FC17 Q33601653-201E9BE2-BCCF-49EA-9FAB-4DC7ACD2E3AC Q33862290-0FA68070-E4F9-4BE1-9750-4174ACC07D6A Q33933626-F23AD2FE-7A96-4673-936A-7B1D373A167D Q34296114-D0C250F5-7C01-4945-B226-C5F8F2C4D209 Q34355748-92FFEBF3-FA5E-4B16-8B22-7FAC58D48736 Q34478129-B231C584-1FCE-4C45-B20B-97556C478899 Q34615545-397B3565-3D0A-4C59-B064-195F4C6DD95D Q34651354-7B5EA268-5CA6-443D-B927-386B3D547094 Q34664078-03560AEC-DB18-444F-B663-B3815A4C4FD3 Q34776985-A1101450-D629-4E23-B5DF-8DFE84F26EBF Q35145369-1E01CD8D-D49D-4C90-961B-F0294A5F6405 Q35208654-290B9539-FDCB-473C-A6EE-7881AE9A7910 Q35274741-125751CB-B6C8-4154-AF98-55A85A313D8A Q35372584-73FF6882-43A5-42FC-9D6C-2E1B783B466A Q35419840-ED4B1487-E860-4FDA-B12A-D6B595D8BECC Q35479665-64D028C5-5FDA-4C2E-9F6D-8FD174CD536E Q35576250-E33DA320-026D-41EE-9628-CB6CACCB269D Q35599629-E910A2DA-1A3D-42E8-ABE5-F8F3186ECA99 Q35663802-28C93BE8-AF03-4C36-A3F8-CE1099DB617E Q35684440-63DFDB77-1F67-4AA8-927E-934BBA510AE4 Q35693389-B329E09E-7D90-404B-AC3F-47978CA3D53E Q35764392-A9F2740D-015B-42C5-B11F-8CDAB3017A67 Q35821286-22FB3D74-C3F2-4204-BAE9-A309D6C26418 Q35861503-7EF6E35A-E3C7-4C42-936E-C41FCA05B615 Q35889941-F7EBA0FC-4712-436C-A2E4-0A9C7C61190E Q36021424-68252C5B-4201-452D-BC57-957BDDE16BBC Q36030226-77BD3245-46F1-4F50-9D60-3A173BE0D1B8 Q36064908-8490BCFE-1435-4375-8DC5-B8DD35B2C0B9 Q36088788-036F1FF8-B09D-4C36-9032-A51505290C5A

P2860

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Item

http://www.wikidata.org/entity/Q34679149

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu